Lipid-based nanosystems for targeting bone implant-associated infections: current approaches and future endeavors

Drug Deliv Transl Res. 2021 Feb;11(1):72-85. doi: 10.1007/s13346-020-00791-8.

Abstract

Bone infections caused by Staphylococcus aureus are a major concern in medical care, particularly when associated with orthopedic-implant devices. The ability of the bacteria to form biofilms and their capacity to invade and persist within osteoblasts turn the infection eradication into a huge challenge. The reduction of antibiotic penetration through bacterial biofilms associated with the presence of persistent cells, ability to survive in the host, and high tolerance to antibiotics are some of the reasons for the difficult treatment of these infections. Effective therapeutic approaches are urgently needed. In this sense, lipid-based nanosystems, such as liposomes, have been investigated as an innovative and alternative strategy for the treatment of implant-associated S. aureus infections, due to their preferential accumulation at infected sites and interaction with S. aureus. This review highlights the recent advances on antibiotic-loaded liposome formulations both in vitro and in vivo and how the interaction with S. aureus biofilms may be improved by modulating the liposomal external surface. Graphical Abstract.

Keywords: Biofilms; Chemotherapy; Intracellular-targeting; Liposomes; Staphylococcus aureus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Biofilms
  • Humans
  • Lipids
  • Staphylococcal Infections* / drug therapy
  • Staphylococcus aureus*

Substances

  • Anti-Bacterial Agents
  • Lipids